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The argument for ‘evidence based medical practice’ is compelling and the ideal protocol of randomized 
controlled studies to obtain higher level evidence is equally sound. However, some peculiarities of African 
countries make the conduct of standard control trials difficult and raise some serious ethical questions over 
claims of good trial practices. It may be difficult to apply the uncertainty principle or clinical equipoise as moral 
underpins for randomization in clinical trials in Africa. A ‘social contract’ argument may be a useful alternative. 
 





‘Evidence based medicine’ can be argued to be a 
justified renaissance in medical practice. The 
principle of best ‘evidence’ acquisition demands 
randomization of patients to alternative treatment 
modalities or comparison of known versus new 
/proposed treatment modalities. 1 One ethical issue is 
how to justify placing a candidate in one treatment 
modality and not the other, since by default; any 
patient wants the best treatment. Various arguments 
have been used for these placements. These 
arguments may not hold true African regions. Can 
they be modified or do we need another moral 
standpoint as a justification? 
 
 
The ethical arguments for randomization 
 
Two principles are now used as moral underpin for 
randomizing patients into trial arms and the one 
applied really depends on whether you are in Europe 
or America. These principles are; ‘The Uncertainty 
principle’2 and ‘Equipoise’.2 The former claims that 
we do not know the ‘best’ treatment for the illness,   
that we genuinely believe that the patient is fit for 
both the trial and known treatment and that we are 
confident in these believes. The central rationale 
being that if the best treatment is “unknown’ then 
people contribute to posterity at no cost (e.g. ‘the best 
treatment’) to themselves. ‘Equipoise’ refers to 
regarding two treatments as equal in prospect. 
Equipoise may be ‘clinical’ or ‘patient’2. Clinical 
equipoise may be ‘Collective’ where the profession at 
large is equally balanced or ‘Individual’ where the 
researcher accepts such a position. Patient’s equipoise 
is better presented than defined, and is observed when 
a group of patients are well informed of the benefits 
and risks of alternative treatment modalities and 
patients that chose any modality as are so treated but 
those undecided are said to be in ‘equipoise’ and 
randomized into the study. These principles are 
themselves conjectural and are still debated. 3 While 
the uncertainty principle is favored in Europe, 
equipoise appears to be the American option. Can 
these principles operate in Africa? What could be the 
moral underpin for randomization of patients into trial 
arms in this region of the world?   
 
 
The defects in “equipoise or uncertainty” in Africa 
 
It can be argued that a primary quality of doctor-
patient relationship is “Trust’. This implies a patient’s
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confidence in the reliability of the doctor and imposes 
a duty of benevolent concern for the interests and 
welfare of the patient (altruism) while respecting the 
patient’s right and capacity to self determination. 
Medicine has no room for utilitarianism (i.e. end 
justifies the means) nor paternalism (like making 
decisions for competent patients). 4 
In most of Africa the ‘best’ treatment is often not 
available and /or unaffordable. 5 The routine practice 
of the clinician may often be ‘the available’ treatment. 
In such circumstance the ‘uncertainty principle’ may 
be difficult to evoke as the clinician is reasonably 
certain there is a better treatment. Also, most trial 
candidate drugs are fresh from the discovery-
production pipeline and are by definition costly. This 
implies that the prospect of contributing to ‘posterity’ 
in the context of the patient’s environment is remote 
(and even more so in in chronic illnesses). The 
justification for pushing an ‘uncertainty’ agenda in 
these situations is to rationalize that the patient may at 
least benefit from the free trial drugs: this is classic 
‘utilitarianism’ with underlying ‘paternalism’ and 
therefore betrays ‘trust’. Thus the ‘uncertainty 
principle’ could be difficult to justify in Africa. 
Given the uncertainty of the ‘uncertainty 
principle’ in Africa, equipoise may be the available 
‘justification’ for randomization. An immediate 
problem is the patient’s autonomy which places 
‘patient equipoise’ superior to ‘collective and/or 
individual’ clinical equipoise. 6 It can be argued that 
patient’s equipoise is the true equipoise of clinical 
trials because clinical equipoise demands beneficence. 
This requires ‘justified true belief’ which may only be 
claimed without the risk of betraying patients’ trust 
after the study.  Patient’s equipoise requires that the 
patient is sufficiently competent and informed to 
make decisions. Most patients in Africa reflect the 
high level of illiteracy. This is clouded by cultural 
taboos and role allocations that often place decision 
making to others like husband, community leaders 
and religious leaders. Detailed information to patients 
in such a context may mean ‘informed scaring of 
patients’7(an ‘unphysician’ approach) while decision 
by others simply imply ‘surrogate’ equipoise.  
 
 
Advocacy for “Social contract” in clinical trials in 
Africa 
 
Africans must take treatments and this implies that 
clinical trials must be conducted. What then, could be 
the moral underpin for randomization? A solution 
could be to apply the “Social contract’2 argument 
which pursues that individuals agree to relinquish 
some of their natural liberties in a civil society for 
collective advantage. This may be patronizing if 
proposed in the context of ‘the human race’ but may 
be tenable if obvious gains to the immediate society 
are contracted. These may include guaranteed supply 
of subsidized test and treatment(s) and obvious 
relevance of the trial to the test community’s disease 
pattern. Clinical trial design may have to be restrictive 
to less risky types like ‘sequential trials’2 where 
outcome are continuously monitored and the trials 
terminated according to predetermined stopping rule 
and ‘crossover studies.’2 This ensures that all patients 
benefit from the available and proven treatment 
modality. Zelen’s design’2 may be particularly useful 
in surgical trials because it compares standard versus 
novel methods. It randomizes patients before seeking 
consents and only needs consent from the trial group. 
The basic principles of patient randomization into 
clinical trials in Africa are difficult to implement. 
Meanwhile, while the need for standard conduct of 
clinical trials anywhere cannot be argued, the realities 
of Africa may compromise such trials. Perhaps subtle 
modifications of trial protocols that do not 
compromise the integrity of the patient may be useful 
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